2019 Step Therapy Criteria

ATYPICALS

Products Affected

Step 2:

- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET
 1 & 2 & 4 & 6 MG ORAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL

Details

Criteria

Claim will pay automatically for Fanapt OR Vraylar if enrollee has a paid claim for at least a 1 days supply of any generic formulary atypical antipsychotic in the past. Otherwise, Fanapt AND Vraylar requires a step therapy exception request indicating: (1) history of inadequate treatment response with any generic formulary atypical antipsychotic, OR (2) history of adverse event with any generic formulary atypical antipsychotic is contraindicated.

2019 Step Therapy Criteria

GLP1-INSULIN

Products Affected

Step 2:

- SOLIQUA SOLUTION PEN-INJECTOR XULTOPHY SOLUTION PEN-100-33 UNT-MCG/ML **SUBCUTANEOUS**
 - INJECTOR 100-3.6 UNIT-MG/ML SUBCUTANEOUS

Criteria	Claim will pay automatically for Xultophy OR Soliqua if enrollee has a paid claim for at least a 1 day supply for step level 1 agent (LANTUS, LEVEMIR, OZEMPIC, TOUJEO, TRESIBA, OR VICTOZA). Otherwise, Xultophy AND Soliqua requires a step therapy exception request indicating: (1) history of inadequate treatment response with step 1 agent, OR (2) history of adverse event with step 1 agent, OR (3) step 1 agent is contraindicated.
----------	--

2019 Step Therapy Criteria

PPI

Products Affected

Step 2:

- DEXILANT CAPSULE DELAYED RELEASE 30 MG ORAL
- DEXILANT CAPSULE DELAYED RELEASE 60 MG ORAL

Details

Criteria Claim will pay automatically for Dexilant if enrollee has a paid claim for at least a 1 days supply of lansoprazole, omeprazole, pantoprazole, or rabeprazole in the past. Otherwise, Dexilant requires a step therapy exception request indicating: (1) history of inadequate treatment response with lansoprazole, omeprazole, pantoprazole, or rabeprazole, OR (2) history of adverse event with lansoprazole, omeprazole, pantoprazole, or rabeprazole, OR (3) lansoprazole, omeprazole, pantoprazole, or rabeprazole is contraindicated.

2019 Step Therapy Criteria

TRELEGY

Products Affected

Step 2:

• TRELEGY ELLIPTA AEROSOL POWDER BREATH ACTIVATED 100-62.5-25 MCG/INH INHALATION

Criteria	Claim will pay automatically for Trelegy if enrollee has a paid claim for at least 1 day supply of Advair Diskus, Breo Ellipta, Serevent Diskus, Spiriva HandiHaler, Spiriva Respimat or Stiolto in the past. Otherwise, Trelegy will require a step therapy exception request indicating: (1) history of inadequate treatment response with STEP 1 Agent, OR (2) history of adverse event with STEP 1 Agent, OR (3) STEP 1 Agent is
	history of adverse event with STEP 1 Agent, OR (3) STEP 1 Agent is contraindicated.

2019 Step Therapy Criteria

TRINTELLIX

Products Affected

Step 2:

- TRINTELLIX TABLET 10 MG ORAL
- TRINTELLIX TABLET 20 MG ORAL

• TRINTELLIX TABLET 5 MG ORAL

Criteria	Claim will pay automatically for trintellix if enrollee has a paid claim for at least a 1 days supply of any 2 generic formulary antidepressants in the past. Otherwise, trintellix requires a step therapy exception request
	indicating: (1) history of inadequate treatment response with any 2 generic formulary antidepressants, OR (2) history of adverse event with any 2 generic formulary antidepressants, OR (3) any 2 generic formulary antidepressants are contraindicated.

2019 Step Therapy Criteria

ULORIC

Products Affected

Step 2:

- ULORIC TABLET 40 MG ORAL ULORIC TABLET 80 MG ORAL

Criteria	Claim will pay automatically for Uloric if enrollee has a paid claim for at least a 1 days supply of Allopurinol in the past. Otherwise, Uloric requires a step therapy exception request indicating: (1) history of
	inadequate treatment response with Allopurinol, OR (2) history of adverse event with Allopurinol, OR (3) Allopurinol is contraindicated.

2019 Step Therapy Criteria

Index

D	T
DEXILANT CAPSULE DELAYED	TRELEGY ELLIPTA AEROSOL
RELEASE 30 MG ORAL3	POWDER BREATH ACTIVATED 100-
DEXILANT CAPSULE DELAYED	62.5-25 MCG/INH INHALATION 4
RELEASE 60 MG ORAL3	TRINTELLIX TABLET 10 MG ORAL 5
F	TRINTELLIX TABLET 20 MG ORAL 5
FANAPT TABLET 1 MG ORAL 1	TRINTELLIX TABLET 5 MG ORAL 5
FANAPT TABLET 10 MG ORAL 1	U
FANAPT TABLET 12 MG ORAL 1	ULORIC TABLET 40 MG ORAL 6
FANAPT TABLET 2 MG ORAL 1	ULORIC TABLET 80 MG ORAL 6
FANAPT TABLET 4 MG ORAL 1	\mathbf{V}
FANAPT TABLET 6 MG ORAL 1	VRAYLAR CAPSULE 1.5 MG ORAL 1
FANAPT TABLET 8 MG ORAL 1	VRAYLAR CAPSULE 3 MG ORAL 1
FANAPT TITRATION PACK TABLET 1	VRAYLAR CAPSULE 4.5 MG ORAL 1
& 2 & 4 & 6 MG ORAL1	VRAYLAR CAPSULE 6 MG ORAL 1
S	VRAYLAR CAPSULE THERAPY PACK
SOLIQUA SOLUTION PEN-INJECTOR	1.5 & 3 MG ORAL 1
100-33 UNT-MCG/ML	X
SUBCUTANEOUS2	XULTOPHY SOLUTION PEN-INJECTOR
	100-3.6 UNIT-MG/ML
	SUBCUTANEOUS2